Search

Your search keyword '"Morisco F"' showing total 918 results

Search Constraints

Start Over You searched for: Author "Morisco F" Remove constraint Author: "Morisco F"
918 results on '"Morisco F"'

Search Results

1. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection

3. T.12.7: EXPRESSION OF DEIODINASES-3 IN HCC AS PREDICTOR OF POOR TUMOR DIFFERENTIATION

8. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

9. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

10. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study

11. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

12. Outcomes of Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced hepatocellular carcinoma in the era of immunotherapy: A real-life comparison with best supportive care

13. Development of a risk score to predict portal vein tumor thrombosis in patients with hepatocellular carcinoma

14. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

15. A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort

21. Lack of substantial improvements in the landscape of alcohol-related hepatocellular carcinoma in the last 15 years: The need to improve cancer prevention and surveillance

22. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

23. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

24. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

25. Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications

26. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

27. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

28. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

29. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

30. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

32. Pattern of macrovascular invasion in hepatocellular carcinoma

34. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

35. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

36. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort

37. Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison

38. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

41. OC.15.2 HUMORAL RESPONSE TO 2-DOSE BNT162B2 MRNA VACCINE FOR COVID-19 IN LIVER TRANSPLANT RECIPIENTS

43. Epidemiological, virological and clinical profile of HBsAg positive individuals in Italian hospital settings: interim results of the HBV/HDV PITER cohort

44. Long-term albumin administration eases the management of hyponatremia in outpatients with decompensated cirrhosis: data from the ANSWER Trial

48. Humoral response to 2-dose BNT162b2 mRNA vaccine for Covid-19 in liver transplant recipients

49. Digestive diseases. 2022-2025 edition

Catalog

Books, media, physical & digital resources